GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis
The National Health Care Institute has completed its assessment whether the medicinal product tirbanibulin (Klisyri®) can be included in the Medicine Reimbursement System (GVS). Tirbanibulin is indicated for the topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. Based on the criteria for interchangeability, it can be concluded that tirbanibulin (Klisyri®) is interchangeable with the other medicinal products in the GVS. The National Health Care Institute advises the Minister to include tirbanibulin on List 1A in cluster 0D06BBADC V of the GVS.
Indication for which reimbursement is requested
Tirbanibulin is available as an ointment with 10 mg/g (1%) tirbanibulin as active ingredient. Each sachet contains 2.5 mg tirbanibulin in 250 mg of ointment. It is indicated for the topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.
Package advice
The National Health Care Institute recommends the Minister to include tirbanibulin on List 1A in cluster 0D06BBADC V of the GVS with 5-fluorouracil, imiquimod and methyl aminolevulinate.